Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
about
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responseClinical applications of PD-L1 bioassays for cancer immunotherapy.Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Prospects and progress of immunotherapy for bladder cancer.The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidenceCheckpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Cancer Immunotherapies: Are They as Effective in the Elderly?Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.Immunotherapy: a new treatment paradigm in bladder cancer.Immune checkpoint inhibitors in challenging populations.Bladder cancer, ESMO 2016.Contemporary update on neoadjuvant therapy for bladder cancer.Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.Targeted therapies for renal cell carcinoma.Immune checkpoint blockade in infectious diseases.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.Product review on the Anti-PD-L1 Antibody Atezolizumab.Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Excellent response to chemotherapy post immunotherapy.Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients with Urothelial Carcinoma.Pembrolizumab in the treatment of advanced urothelial cancer.
P2860
Q32177609-847543BB-E321-4C78-9221-9719C6FAA4C7Q33702815-DBC58C40-27FB-43D5-9EAD-A21F266C0431Q33819820-1C4E987A-814B-463B-BEA2-0F13E4F67B07Q33850467-F651AAE2-A1D5-4A8D-96B1-474D147962A5Q38612818-FF466F35-D456-4A5A-A596-9E8063374EB2Q38612965-4DB27C2F-0E06-465E-AC27-824E8A70B045Q38621223-713F6CE8-8860-4FF5-B4C3-E61097F4509EQ38621228-7097EA48-DB72-4756-BE2A-082F056672DAQ38649562-F1FA1935-8400-4DF7-BFEB-05567829060CQ38672084-E52EB228-CA70-49F9-B33F-0C9F88DACF3DQ38679662-2914A684-0944-445C-8677-C2EDB7C44A96Q38685278-3CEED713-F65F-4356-96C1-2A8F26B859F9Q38737781-F6F07FB8-2919-41F8-957A-10A2E9A2C1A4Q38743589-51147813-9E72-4D3E-A41C-0EAD02DDAF56Q38939708-00FAC741-1E47-494D-B6A1-28DD6D238A1EQ39103701-CB00EB08-DE6E-4DE9-82E4-F0EB014652ABQ39177293-0888ADA5-71A6-432C-949D-7DD9581E7AA6Q39208496-E1B2F540-B00D-4A76-8F72-97A2514BE666Q39243064-D824AB4E-570D-44C3-83D4-551E2BCEC6F7Q39425380-26A15615-7266-474C-BC28-1AA2F5EF9E1BQ41921732-BAA42297-029A-4420-9A9B-784D070AF217Q42375254-3B315E52-D23E-413A-A99C-1612142BDA04Q45074483-A6FD2245-9D5F-4AE1-B241-325C3C1E41ACQ45242086-613F91FF-E0DC-47DD-8D64-7B5C83887D56Q45870820-9C20504A-48DB-4455-8B21-77257C403A4EQ45968787-25209BE9-B27B-48BC-A473-EF2EBBEA728FQ46129475-B312728B-5BC5-4B8D-96ED-50608E3F5EF7Q47101155-83FFB8C5-6752-4F1E-9CB8-A09B44E1DDCFQ47103525-34E331E2-D86B-418C-A0C0-FC4786B40166Q47120629-EB86A546-86CD-4E7A-A94C-0CBC91680E2CQ47143259-5266561A-4274-44FF-9FDD-B3E59EDC4BA2Q47157402-8092B13D-AF3A-467C-A306-4350C4A02383Q47201278-DEA85AB7-9F56-48D6-B1A2-3BE91CC5A024Q47221234-E647DA4D-A1DF-4200-8851-928034A97734Q47259728-5CC6A49A-B584-421F-9CE7-66F00829922BQ47261543-F77F0169-ED97-41DD-BB7A-D1DA92B5D361Q47277879-E0DE4FBF-8EC9-49EC-9FB2-6A93B197DC5EQ47278600-080F8D53-24A0-4E76-83B6-60830E844A2FQ47305852-007BC16C-FEEE-4B1D-939B-35BD6DE9E249Q47345366-71FCA10D-1832-48A9-B9A8-22ED7600E83B
P2860
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Atezolizumab as first-line tre ...... m, multicentre, phase 2 trial.
@ast
Atezolizumab as first-line tre ...... m, multicentre, phase 2 trial.
@en
type
label
Atezolizumab as first-line tre ...... m, multicentre, phase 2 trial.
@ast
Atezolizumab as first-line tre ...... m, multicentre, phase 2 trial.
@en
prefLabel
Atezolizumab as first-line tre ...... m, multicentre, phase 2 trial.
@ast
Atezolizumab as first-line tre ...... m, multicentre, phase 2 trial.
@en
P2093
P2860
P50
P921
P1433
P1476
Atezolizumab as first-line tre ...... rm, multicentre, phase 2 trial
@en
P2093
Alexandra Drakaki
AnnChristine Thåström
Daniel P Petrylak
David I Quinn
David R Shaffer
Dean F Bajorin
Edward E Kadel
Gregg D Fine
IMvigor210 Study Group
P2860
P356
10.1016/S0140-6736(16)32455-2
P407
P577
2016-12-08T00:00:00Z